For cortical `disconnection’ in aging and Alzheimer’s illness. Neurobiol Aging 2004, 25:843?51. 34. Marner L, Nyengaard JR, Tang Y, Pakkenberg B: Marked loss of myelinated nerve fibers within the human brain with age. J Comp Neurol 2003, 462:144?52. 35. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T: Elevated AOu-Yang and Van Nostrand Journal of Neuroinflammation 2013, 10:134 http://jneuroinflammation/content/10/1/Page 11 of36.37.38.39. 40.41.42.43.44.45.46.47.48.49. 50.51. 52.53.54.55.peptides and lowered cholesterol and myelin proteins characterize white matter degeneration in Alzheimer’s disease. Biochemistry 2002, 41:11080?1090. Mitew S, Kirkcaldie MT, Halliday GM, Shepherd CE, Vickers JC, Dickson TC: Focal demyelination in Alzheimer’s illness and transgenic mouse models. Acta Neuropathol 2010, 119:567?77. Molineaux SM, Engh H, de Ferra F, Hudson L, Lazzarini RA: Recombination inside the myelin basic protein gene developed the dysmyelinating shiverer mouse mutation. Proc Natl Acad Sci USA 1986, 83:7542?546. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, Guillozet-Bongaarts A, Ohno M, Disterhoft J, Van Eldik L, Berry R, Vassar R: Intraneuronal -amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s illness mutations: potential variables in amyloid plaque formation. J Neurosci 2006, 26:10129?0140. Liu L, Duff K: A strategy for serial collection of cerebrospinal fluid in the cisterna magna in mouse. J Vis Exp 2008, 21:960. Davis J, Xu F, Deane R, Romanov G, Previti ML, Zeigler K, Zlokovic BV, Van Nostrand WE: Early-onset and robust cerebral microvascular accumulation of amyloid -protein in transgenic mice expressing low levels of a vasculotropic Dutch/Iowa mutant kind of amyloid -protein precursor. J Biol Chem 2004, 279:20296?0306. DeMattos RB, Bales KR, Parsadanian M, O’Dell MA, Foss EM, Paul SM, Holtzman DM: Plaque-associated disruption of CSF and plasma amyloid- (A) equilibrium within a mouse model of Alzheimer’s disease. J Neurochem 2002, 81:229?36. Liao MC, Hoos MD, Aucoin D, Ahmed M, Davis J, Smith SO, Van Nostrand WE: N-terminal domain of myelin standard protein inhibits amyloid -protein fibril assembly. J Biol Chem 2010, 285:35590?5598. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM: A immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates by way of the proteasome.Price of 167073-08-7 Neuron 2004, 43:321?32.2-Bromo-4-formylnicotinonitrile web Gyure KA, Durham R, Stewart WF, Smialek JE, Troncoso JC: Intraneuronal a-amyloid precedes development of amyloid plaques in Down syndrome.PMID:24456950 Arch Pathol Lab Med 2001, 125:489?92. Wirths O, Multhaup G, Czech C, Blanchard V, Moussaoui S, Tremp G, Pradier L, Beyreuther K, Bayer TA: Intraneuronal a accumulation precedes plaque formation in -amyloid precursor protein and presenilin-1 doubletransgenic mice. Neurosci Lett 2001, 306:116?20. Kayed R, Head E, Sarsoza F, Saing T, Cotman CW, Necula M, Margol L, Wu J, Breydo L, Thompson JL, Rasool S, Gurlo T, Butler P, Glabe CG: Fibril distinct, conformation dependent antibodies recognize a generic epitope typical to amyloid fibrils and fibrillar oligomers that is definitely absent in prefibrillar oligomers. Mol Neurodegener 2007, 2:18. Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, Holtzman DM, Miller CA, Strickland DK, Ghiso J, Zlokovic BV: Clearance of Alzheimer’s amyloid-ss(1?0) peptide from brain by LDL receptor-related protein-1 at the.